New Aspects for the Treatment of Cardiac Diseases Based on the Diversity of Functional Controls on Cardiac Muscles: Effects of Targeted Disruption of the Type 5 Adenylyl Cyclase Gene

DOI Web Site PubMed 12 Citations 45 References
  • Okumura Satoshi
    Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Japan
  • Suzuki Sayaka
    Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Japan
  • Ishikawa Yoshihiro
    Cardiovascular Research Institute, Yokohama City University Graduate School of Medicine, Japan Cardiovascular Research Institute, Department of Cell Biology & Molecular Medicine and Medicine (Cardiology), New Jersey Medical School of UMDNJ, USA

Bibliographic Information

Other Title
  • Effects of targeted disruption of the type 5 adenylyl cyclase gene

Search this article

Abstract

Cyclic AMP (cAMP) is known to play a major role in regulating cardiac function. Difference in adenylyl cyclase (AC) isoforms is a potential mechanism by which the cAMP signal, a common second messenger signal, can be regulated in a tissue-specific manner. However, the physiological significance of expressing multiple AC isoforms in a tissue and how each specific isoform regulates the cAMP signal remains poorly understood. In a genetically engineered mouse model in which the expression of the type 5 AC is knocked out (AC5KO), we identified the attenuation of autonomic regulation and calcium-mediated inhibition of cardiac function. We also identified that disruption of type 5 AC preserves cardiac function in response to chronic pressure-overload and catecholamine stress, at least in part, through the inhibition of cardiac apoptosis, which plays a major role in the development of heart failure. The protection against both apoptosis and development of cardiac dysfunction induced by left ventricular pressure overload in AC5KO makes this molecule potentially important for developing future pharmacotherapy, where suppressing the activity of type 5 AC, and not the entire β-adrenergic signaling (β-AR) signaling pathway, may have an advantage over the current β-AR–blockade therapy in the treatment of heart failure.<br>

Journal

Citations (12)*help

See more

References(45)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top